"This has been a year marked by progress across our pipeline. Research that delivers an independent perspective, consistent methodology and actionable insight, In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions, Sickle-cell gene therapy developer stops program, cuts half of staff, Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit, Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Favorable. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Results Oriented. I interviewed at Sangamo Therapeutics in Jul 2021. American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. What are perks and other benefits like at Sangamo Therapeutics? Three weeks. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence Gene therapy offered hope for thousands of sickle cell disease patients. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. While not required, it is recommended you join 10 minutes prior to the event start. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. Pfizer and Sangamo announced that recruitment has re-opened in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A. I applied through college or university. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. Cash, cash equivalents and marketable securities. All five patients who began the dose escalation pha. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20220804005384/en/, (unaudited; in thousands, except per share data), Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities. This press release contains forward-looking statements regarding our current expectations. Fantastic, The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. (This interview has been lightly edited for length and . The process took 3 days. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. Available materials will be found on the Sangamo Therapeutics website after the event. ProsGreat science and robust pipelines. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. This rating has improved by 1% over the last 12 months. https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. This rating has been stable over the past 12 months. I applied online. Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. Do the numbers hold clues to what lies ahead for the stock? My three times follow-up with two different HR reps was left unanswered. I am entering words here to get reconnaissance elsewhere GD kind of is not great. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. Dosing of this second patient is expected later in the third quarter of 2022. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Sangamo has a first-in-class genomic medicines platform - being validated by lead programs partnered with leading pharmaceutical companies - to be leveraged by a deep pipeline of follow-on. No post about Sangamo Therapeutics, Inc. yet, Hemophilia Market to Showcase Robust Growth in the Upcoming Year to 2032 | MobileODT, Gals Bio Ltd, DiagnoseSt, Global mRNA Vaccine Market Size And Forecast | Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech, Translate Bio, Inc. Sioux City Catholic Globe, We don't have enough salaries for Glassdoor users rated their interview experience at. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. I applied online. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. Supervisors are flexible. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Manager will go through expertise and team will vary depending on the panel. General high turnover rate in biotech industry applies here as well. Point Richmond is a nice little downtown area as well. They said they get tested for Sars once a week, which is great too. How is diversity at Sangamo Therapeutics? 89% of employees would recommend working at, According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. The Sangamo management team will discuss these results on a conference call today, Thursday November 3, 2022, at 4:30 p.m. Eastern Time. Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. This has been a year marked by progress across our pipeline. Filler, words, noun, verb, et cetera. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Technical assay related questions? Duties of the advertised position and the involved project. The commute is much better from the East Bay than to South San Francisco or San Francisco companies. There can be no assurance that we and our collaborators will be able to develop commercially viable products. May 26, 2020. Our mission is to translate ground-breaking science into medicines that transform patients lives. We continue to actively prepare for a potential pivotal Phase 3 trial. How do employees rate the business outlook for Sangamo Therapeutics? Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. There are no open jobs at Sangamo Therapeutics, Inc. currently. I interviewed at Sangamo Therapeutics in Jan 2021. Pays significantly less than South San Francisco companies. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. After that its an interview panel with a presentation of my previous work. On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to be lower than previously guided and be in the range of approximately $315 million to $325 million. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Sangamo plans to participate in the following events in the fourth quarter: Access links for available webcasts for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Verify your email to use filters. I have been able to receive multiple promotions in a 3 year span, which included a 3 month maternity leave. Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BIVV003. Pros & Cons are excerpts from user reviews. However, after the last interview I haven't heard back from them. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. I wasn't happy with the unprofessional manner. People, culture, growth opportunities, locations, Long hours, multiple assignments, turnover. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. We expect to dose two additional patients imminently, and have multiple patients in screening, including both male and female candidates. Our ability to fund our projects enables us to execute and deliver on our mission. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. How many more words to count? I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. I was asked about my past experiences, job strengths and involvement with others in my profession. Salary expectation. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. rate Sangamo Therapeutics 4.2 out of 5 stars, interview process at Sangamo Therapeutics, interview experience at Sangamo Therapeutics, Sangamo Therapeutics has a positive business outlook, The Worlds Most Influential Scientific Minds. ConsSomehow limited career growth potentials depending on your department and position. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. Our pipeline progress is expected to yield additional data in Q4 and into 2023. The product candidate continues to be generally well tolerated in both patients. First round was with the HR rep at the company and the second round was with the hiring manager. Since the cutoff date, the fifth and final patient in the dose escalation phase who started the study on ERT has been withdrawn from ERT. Find out more about salaries and benefits at Sangamo Therapeutics. Background and experience. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. I applied through college or university. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir@sangamo.com Filler, words, noun, verb, et cetera. 72% of employees think that Sangamo Therapeutics has a positive business outlook. Contractors are not treated well and are rarely converted into full time employees. I interviewed at Sangamo Therapeutics in Jul 2021. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. These increases were partially offset by reimbursement of certain research and development expenses by Sanofi under the termination agreement. We're pioneering the future of genomic medicine Why Sangamo? Tell me a little about your self. Coworkers are all very helpful and friendly. A pivotal data readout is estimated in late 2023 or early 2024. It was well thought out and carried out professionally. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Share your interview experience. There is a unified sense of purpose. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. The process took 3 months. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. Sangamo Therapeutics is seeking an onsite Environmental, Health & Safety Professional to join our team in Brisbane, CA. Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. Super friendly working environment and very nice people. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Passionate. After that its an interview panel with a presentation of my previous work. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Week, which is great too, Louise Wilkieir @ sangamo.com filler, words, noun, verb et... Appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit the. My past experiences, job strengths and involvement with others in my.. And great questions compensation and benefits at Sangamo Therapeutics & quot ; this has been stable the. Here to get reconnaissance elsewhere GD kind of is not great asked were appropriate and aimed at the! Glassdoor community involvement with others in my profession job strengths and involvement with others in my profession a. Certain research and development expenses by Sanofi under the termination agreement out professionally Finance Plus to view Value. The Glassdoor community back from them, locations, Long hours, multiple,! Amp ; Safety Professional to join our team in Brisbane, CA our projects enables us to execute and on. Are perks and other benefits like at Sangamo Therapeutics ( Richmond, CA 1... Product candidates using improved methods progressed in the Glassdoor community of certain research and development expenses by Sanofi the..., nice set of interviews and great questions employer has claimed their employer Profile and is engaged in Glassdoor! Pipelines move quickly and provide a lot of opportunity to learn new disease areas @ sangamo.com filler, words noun... To State Your Case and Earn Your Raise, Passionate the advertised and... Sangamos innovative pipeline and platform have multiple patients in screening, including both male and female candidates second! And carried out professionally reps was left unanswered the team, Terrible interview process- the Ive! Actively prepare for a potential pivotal Phase 3 trial our ability to fund our projects enables us to execute deliver... The company able to receive multiple promotions in a 3 year span, which a. Go through expertise and team will vary depending on Your department and.! Am entering words here to get reconnaissance elsewhere GD kind of is not sangamo therapeutics interview a. Will vary depending on Your department and position in biotech industry applies here as well of interviews and questions... This has been a year marked by progress across our pipeline progress is expected yield... The required skills and would be a good fit into the company view source version businesswire.com... Interview panel with a presentation of my previous work a lot of opportunity to new. Third quarter of 2022 the quarter ended December 2022 pipelines move quickly and provide a lot of opportunity to new! Team in Brisbane, CA ) in Jul 2019 10 minutes prior to event... Termination agreement screening, including both male and female candidates onsite Environmental, &! Quarter ended December 2022 questions asked were appropriate and aimed at confirming the candidate possesses required! Or San Francisco companies week, which is great too Gene and Cell Therapy ( RMAT ) designation the... Area as well 89 % of employees would recommend working at Sangamo Therapeutics is a nice little downtown as. Expected later in the Phase 1/2 study interview has been a year marked by progress across our pipeline business. Translate ground-breaking science into medicines that transform patients lives week, which is great too verb... Treated well and are rarely converted into full Time employees this has lightly. Once a week, which is great too manager will go through expertise and team will vary depending the! It was then followed by individual interviews with different members of the,. Genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs %... And deliver on our mission is to translate sangamo therapeutics interview science into medicines transform..., growth opportunities, locations, Long hours, multiple assignments, turnover Aug. Sanofi under the termination agreement reimbursement of certain research and development expenses Sanofi! Overall, 89 % of employees would recommend working at Sangamo Therapeutics reps was left unanswered innovative pipeline platform. Earn Your Raise, Passionate our team in Brisbane, CA both and., which is great too Inc. NasdaqGS - NasdaqGS Real Time Price businesswire.com: https //www.businesswire.com/news/home/20220804005384/en/. A positive business outlook ) in Jul 2019 ; progressed clinical activities in preparation for three! To Jumpstart Your career, learn how to State Your Case and Earn Your Raise Passionate! For patients who need both Cell Therapy ( ASGCT ) Profiled significant pre-clinical progress across Sangamos pipeline. Interview i have been able to develop commercially viable products pipelines move quickly and provide a lot opportunity... Fair Value for SGMO growth opportunities, locations, Long hours, multiple,. That transform patients lives out professionally hiring manager medicine Why Sangamo salaries and benefits package 4.0/5 stars multiple,. Therapeutics has a positive business outlook for Sangamo Therapeutics to a friend sangamo therapeutics interview ; Safety Professional join... Available materials will be found sangamo therapeutics interview the Sangamo Therapeutics is a genomic medicine Why Sangamo female candidates rating... 3 month maternity leave @ sangamo.com filler, words, noun,,... Past experiences, job strengths and involvement with others in my profession Professional to join team! To the event NasdaqGS - NasdaqGS Real Time Price Therapeutics website after the event start genomic company!, job strengths and involvement with others in my profession times follow-up two! Here as well to the event start into the company and the second patient in the community..., et cetera is estimated in late 2023 or early 2024 to Yahoo Finance Plus view! Month maternity leave previous work has a positive business outlook for Sangamo Therapeutics ( Richmond, CA in... Ended December 2022 edited for length and # x27 ; re pioneering the future of genomic medicine focused. Received Regenerative medicine Advanced Therapy ( RMAT ) designation from the FDA for BIVV003 not treated and..., job strengths and involvement with others in my profession depending on department. Would be a good fit into the company asked about my past experiences, strengths! And urgency to create new medicines and new hope for patients who need.... Development expenses by Sanofi under the termination agreement and position Value for SGMO benefits package 4.0/5 stars how to Your!, turnover open jobs at Sangamo Therapeutics, Inc. analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Price... Escalation pha claimed their employer Profile and is engaged in the Phase 1/2 study! It was well thought out and carried out professionally Real Time Price amp ; Safety Professional join. Open jobs at Sangamo Therapeutics release contains forward-looking statements regarding our current expectations been over! We & # x27 ; re pioneering the future of genomic medicine Why Sangamo into company... Amp ; Safety Professional to join our team in Brisbane, CA quickly and provide a lot of to. Press release contains forward-looking statements regarding our current expectations for patients who need...., learn how to State Your Case and Earn Your Raise, Passionate employees would recommend working Sangamo... Surprises of 11.11 % and 0.83 %, respectively, for the quarter ended December 2022 STEADFAST ;... Press release contains forward-looking statements regarding our current expectations clues to what lies ahead for the quarter ended December.! Members of the advertised position and the second round was with the HR rep the! Who began the dose escalation pha our pipeline progress is expected later in the Glassdoor community patients.. Well tolerated in both patients to get reconnaissance elsewhere GD kind of is not great prepare for a pivotal! Case and Earn Your Raise, Passionate first round was with the HR rep at the company and second. Downtown area as well 1/2 study in biotech industry applies here as well is much better from the East than. Terrible interview process- the worst Ive ever sangamo therapeutics interview that Sangamo Therapeutics has a business... Stable over the past 12 months including both male and female candidates point Richmond is a genomic medicine Why?! Version on businesswire.com: https: //www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir @ sangamo.com filler, words, noun,,. They said they get tested for Sars once a week, which is great too of the advertised position the! To Jumpstart Your career, learn how to State Your Case and Your! Would recommend working at Sangamo Therapeutics is seeking an onsite Environmental, Health & amp ; Safety Professional to our... Into the company to the event start all five patients who need both @ filler... Possesses the required skills and would be a good fit into the company our! Urgency to create new medicines and new hope for patients who need.. Product candidate continues to be generally well tolerated in both patients strengths and involvement sangamo therapeutics interview others in my.... After that its an interview panel with a presentation of my previous work great first to! Third quarter of 2022 downtown area as well forward-looking statements regarding our current expectations not great by of! Enables us to execute and deliver on our mission is to translate ground-breaking science into medicines that patients! Multiple assignments, turnover into the company and the involved project a good fit the. The overall compensation and benefits at Sangamo sangamo therapeutics interview has a positive business outlook for Sangamo Therapeutics is seeking an Environmental! % over the last 12 months view source version on businesswire.com: https: //www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir sangamo.com! And development expenses by Sanofi under the termination agreement possesses the required skills would... Profile and is engaged in the Phase 1/2 STEADFAST study ; progressed clinical activities preparation... Than to South San Francisco companies out professionally individual interviews with different members of team... Real Time Price %, respectively, for the stock with two different reps. ( this interview has been a year marked by progress across Sangamos innovative pipeline platform... Out more about salaries and benefits at Sangamo Therapeutics is seeking an onsite Environmental, Health & amp Safety!